BL Pharmtech비엘팜텍
065170 · KOSDAQ · ₩065170 · 비엘팜텍
- Market cap
- ₩52B
- Enterprise value
- ₩49B
- P/E
- —
- P/B
- 6.3×
- Dividend yield
- 0.0%
- ROE
- −192.2%
- Net margin
- −517.9%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−77.1% from the high
₩376Today: ₩1,845 – ₩1,960₩8,150
Returns
- 1W−6.1%
- 1M−21.9%
- 3M−20.6%
- 6M−22.7%
- YTD+241.2%
- 1Y+175.8%
- Volume today
- 193,572
- 0.4× the 20-day average
- Traded today
- ₩368M
- Listed shares
- 27,913,793
- EPS (12 months)
- −₩573
- Earnings yield −30.7%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 30 of 100 (50 is a normal day for this stock).
- MomentumWeak-16.9% over the last month; the price is below its 20-day average.
Signals describe activity, not recommendations. Not financial advice.
BL Pharmtech stock overview
BL Pharmtech (비엘팜텍, KRX: 065170) is listed on KOSDAQ, in the Retail & Trade sector. The company operates through three business divisions: healthy living products such as health functional foods sold via TV home shopping, online malls and other channels, in vitro diagnostic medical devices (including the Gainpad self-sampling device for cervical cancer and STD testing), and anticancer drug development through its related company BL Melanis, which is developing ML301 and ML302 candidates. Its shares closed at ₩1,870 on Oct 27, 2026, up 2.07% on the day, giving it a market value of ₩52B.
Key facts
- Market cap
- ₩52B
- Sector
- Retail & Trade
- Latest price change
- +2.07%
- As of
- Oct 27, 2026
- Main business
- The company operates through three business divisions: healthy living products such as health functional foods sold via TV home shopping, online malls and other channels, in vitro diagnostic medical devices (including the Gainpad self-sampling device for cervical cancer and STD testing), and anticancer drug development through its related company BL Melanis, which is developing ML301 and ML302 candidates.
Quick answers about BL Pharmtech
- What does BL Pharmtech do?
- The company operates through three business divisions: healthy living products such as health functional foods sold via TV home shopping, online malls and other channels, in vitro diagnostic medical devices (including the Gainpad self-sampling device for cervical cancer and STD testing), and anticancer drug development through its related company BL Melanis, which is developing ML301 and ML302 candidates. Its health products are manufactured by contract manufacturers and distributed directly to consumers, mainly in Korea.
- What is the market cap of BL Pharmtech?
- The market capitalisation of BL Pharmtech was ₩52B at the close on Oct 27, 2026.
- Who are the largest shareholders of BL Pharmtech?
- According to the latest official filings, the largest reported holders are Park Yeong-cheol (25.90%, as of Jan 21, 2026); Sangsang Contents Investment Partnership (6.60%, as of Mar 23, 2026); Shin Dong-jin (1.22%, as of Feb 27, 2025).
- When is the next earnings report from BL Pharmtech?
- Korean companies rarely announce results dates in advance. Based on when BL Pharmtech filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
Company profile
The company operates through three business divisions: healthy living products such as health functional foods sold via TV home shopping, online malls and other channels, in vitro diagnostic medical devices (including the Gainpad self-sampling device for cervical cancer and STD testing), and anticancer drug development through its related company BL Melanis, which is developing ML301 and ML302 candidates. Its health products are manufactured by contract manufacturers and distributed directly to consumers, mainly in Korea.
Written by AI from the company's latest annual report.
- Korean name
- 비엘팜텍
- Sector
- Retail & Trade
- Themes
- Pharmaceuticals
- CEO
- 박영철
- Founded
- Feb 1995
- Listed
- Nov 2002
- Listed shares
- 27,913,793
- Fiscal year ends
- Month 12
- Website
- www.blpharmtech.com
Similar companies
- Samsung C&T028260 · ₩49T₩301,000+3.08%
- POSCO International047050 · ₩8.8T₩49,850+0.61%
- ISC095340 · ₩3.2T₩151,300+7.61%
- Youngone111770 · ₩3T₩68,100+1.04%
- Dong SUH Companies026960 · ₩2.7T₩27,500+0.73%
- Shinsegae004170 · ₩2.3T₩245,0000.00%
- SK Gas018670 · ₩2.3T₩249,000−0.80%
- Lotte Shopping023530 · ₩2.3T₩81,300−0.12%
Recent filings
See all- Amended: Acquisition of shares in another companySep 10, 2026
- Half-year report (Jun 2026)Aug 14, 2026
- Acquisition of shares in another companyJul 13, 2026
- Amended: Convertible bond issue decisionJun 15, 2026
- Quarterly report (Mar 2026)May 15, 2026
Titles in Korean until English translations are added.
Also known as: BL Pharmtech / 비엘팜텍 / 065170 / KRX:065170
Source: KRX statistical information